Literature DB >> 17951225

Outcomes research in cancer symptom management trials: the Radiation Therapy Oncology Group (RTOG) conceptual model.

Deborah Watkins Bruner1.   

Abstract

The Radiation Therapy Oncology Group (RTOG) Health Services Research and Outcomes (HSRO) Committee aims to guide the study of the interactions among clinical, humanistic, and economic variables that optimize patient outcomes on clinical trials. To guide this work, the RTOG Outcomes Model was developed. Within this framework, measurement focuses primarily on patient-reported outcomes (PROs). In the examples presented, these outcomes have served to better quantify the benefit of one therapy over alternative therapies, as in the example of multimodality therapy for lung cancer, and to add evidence to clinical outcomes when clinical outcomes alone have not been strong enough to change clinical practice, as in the example of palliative radiotherapy for painful bone metastasis. The unique contribution to the RTOG of the HSRO Committee is the selection and use of PRO measures that give "voice" to the patient in clinical trials as well as provide data to better manage symptoms.

Entities:  

Mesh:

Year:  2007        PMID: 17951225     DOI: 10.1093/jncimonographs/lgm004

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  7 in total

1.  Taking PROs and patient-centered care seriously: incremental and disruptive ideas for incorporating PROs in oncology practice.

Authors:  Molla Sloane Donaldson
Journal:  Qual Life Res       Date:  2008-11-09       Impact factor: 4.147

2.  Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study.

Authors:  Anamaria R Yeung; Stephanie L Pugh; Ann H Klopp; Karen M Gil; Lari Wenzel; Shannon N Westin; David K Gaffney; William Small; Spencer Thompson; Desiree E Doncals; Guilherme H C Cantuaria; Brian P Yaremko; Amy Chang; Vijayananda Kundapur; Dasarahally S Mohan; Michael L Haas; Yong Bae Kim; Catherine L Ferguson; Snehal Deshmukh; Deborah W Bruner; Lisa A Kachnic
Journal:  J Clin Oncol       Date:  2020-02-19       Impact factor: 44.544

Review 3.  Metrics to assess quality of life after management of early-stage lung cancer.

Authors:  Jeff A Sloan
Journal:  Cancer J       Date:  2011 Jan-Feb       Impact factor: 3.360

4.  Low interrater reliability in grading of rectal bleeding using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity scales: a survey of radiation oncologists.

Authors:  Minh-Phuong Huynh-Le; Zhe Zhang; Phuoc T Tran; Theodore L DeWeese; Daniel Y Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-13       Impact factor: 7.038

5.  Comparing dosimetric and cancer control outcomes after intensity-modulated radiation therapy and tomotherapy for advanced cervical cancer.

Authors:  Dapeng Li; Dandan Wang; Shuai Feng; Quancai Chen; Xiugui Sheng; Jue Jia; Xiaohui Yan; Jian Zhu; Yueju Yin
Journal:  Oncol Lett       Date:  2022-05-31       Impact factor: 3.111

6.  Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.

Authors:  Alan L Shields; Yanni Hao; Meaghan Krohe; Andrew Yaworsky; Iyar Mazar; Catherine Foley; Faisal Mehmed; Denise Globe
Journal:  Am Health Drug Benefits       Date:  2016-06

Review 7.  Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

Authors:  Bryce B Reeve; Sandra A Mitchell; Amylou C Dueck; Ethan Basch; David Cella; Carolyn Miller Reilly; Lori M Minasian; Andrea M Denicoff; Ann M O'Mara; Michael J Fisch; Cynthia Chauhan; Neil K Aaronson; Corneel Coens; Deborah Watkins Bruner
Journal:  J Natl Cancer Inst       Date:  2014-07-08       Impact factor: 13.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.